Wall Street brokerages forecast that Guardant Health Inc (NASDAQ:GH) will post earnings per share of ($0.34) for the current quarter, according to Zacks. Four analysts have made estimates for Guardant Health’s earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.36). The company is scheduled to announce its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that Guardant Health will report full-year earnings of ($1.46) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.36). For the next financial year, analysts expect that the firm will report earnings of ($1.05) per share, with EPS estimates ranging from ($1.41) to ($0.88). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Guardant Health.
Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.05. The business had revenue of $36.66 million during the quarter, compared to analyst estimates of $32.12 million.
Several equities analysts have issued reports on GH shares. William Blair reissued an “outperform” rating on shares of Guardant Health in a research note on Wednesday, March 13th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Zacks Investment Research downgraded Guardant Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Bank of America restated a “neutral” rating and set a $60.00 price objective (up previously from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. Finally, Canaccord Genuity initiated coverage on Guardant Health in a report on Tuesday, April 16th. They set a “buy” rating and a $90.00 price objective for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $83.50.
In other Guardant Health news, Chairman Amirali Talasaz sold 232,460 shares of the company’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $65.60, for a total value of $15,249,376.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Vision Fund (Aiv M1) Softbank acquired 2,033,990 shares of Guardant Health stock in a transaction on Tuesday, March 12th. The stock was acquired at an average price of $9.83 per share, with a total value of $19,994,121.70. The disclosure for this purchase can be found here. Insiders have sold 975,338 shares of company stock valued at $66,706,026 in the last quarter.
A number of large investors have recently made changes to their positions in the business. Temasek Holdings Private Ltd bought a new position in Guardant Health in the 4th quarter valued at $60,633,000. Orbimed Advisors LLC bought a new position in Guardant Health in the 4th quarter valued at $57,681,000. BlackRock Inc. grew its stake in Guardant Health by 1.6% in the 1st quarter. BlackRock Inc. now owns 1,132,826 shares of the company’s stock valued at $86,888,000 after purchasing an additional 18,315 shares during the period. Jennison Associates LLC bought a new position in Guardant Health in the 4th quarter valued at $31,700,000. Finally, Lord Abbett & CO. LLC bought a new position in Guardant Health in the 4th quarter valued at $20,024,000. Hedge funds and other institutional investors own 68.54% of the company’s stock.
GH traded up $2.09 during trading on Monday, hitting $78.27. The company’s stock had a trading volume of 1,035,166 shares, compared to its average volume of 1,001,497. Guardant Health has a twelve month low of $27.04 and a twelve month high of $106.58. The firm has a market cap of $6.82 billion and a PE ratio of -27.95.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.